Cardinal Health
The health-care services outfit announced Wednesday that it signed a multiyear agreement with Eli Lilly
Drug distributors such as Cardinal, McKesson
The pharmaceutical industry is notoriously cagey about changing business practices, in part because of the regulatory requirements they face in many areas. However, Lilly's decision likely will help accelerate other firms to move toward the new fee-for-service model. Indeed, Cardinal is already working hard to hammer out details for similar fee-for-service deals with other major pharmaceutical companies, according to Reuters.
One notable aspect of the contract with Eli Lilly, though, is that the agreement expands on existing relationships between the two firms. Cardinal noted in its press release that besides distribution, its dealings with Lilly include drug development and manufacturing. Cardinal's ability to offer this bundle of services to pharma customers could give it a competitive advantage over pure play rivals. In addition, by offering a suite of services to clients, Cardinal may be able to offset any potential thinning of margins in its distribution business.
For more on Cardinal, check out these takes:
Be sure to also check out our Cardinal Health discussion board.
Fool contributor Brian Gorman is a freelance writer living in Chicago. He does not own shares of any companies mentioned here.